Fulcrum Therapeutics(US:FULC)2025-10-29 11:05Financial Performance - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $200.6 million, down from $241.0 million as of December 31, 2024, reflecting a decrease of $40.4 million primarily due to operating activities [10]. - The net loss for Q3 2025 was $19.6 million, compared to a net loss of $21.7 million in Q3 2024, indicating an improvement in financial performance [10]. - The company expects its current cash position to fund operations into 2028, ensuring financial stability for ongoing projects [6]. Research and Development - Research and development expenses for Q3 2025 were $14.3 million, slightly down from $14.6 million in Q3 2024, attributed to reduced costs from the discontinuation of the losmapimod program [10]. - Fulcrum plans to submit an investigational new drug application (IND) for the treatment of bone marrow failure syndromes in Q4 2025 [4]. - Fulcrum aims to present additional clinical data at the 67th American Society of Hematology Congress in December 2025 [4]. Clinical Trials - The Phase 1b PIONEER trial of pociredir showed a clinically meaningful increase in fetal hemoglobin (HbF) levels, with no drug-related serious adverse events reported [4]. - Enrollment in the 20 mg dose cohort of the PIONEER trial was completed, achieving over 90% adherence to the study drug [4]. Regulatory Designations - Pociredir has received FDA Fast Track designation and Orphan Drug Designation for the treatment of sickle cell disease [8]. Administrative Expenses - General and administrative expenses decreased to $7.6 million in Q3 2025 from $8.4 million in Q3 2024, primarily due to lower professional services costs [10].